{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-24-000155","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.867526+00:00","generated_at":"2026-05-31T15:31:46.397729+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pfizer Q2 adj EPS $0.60, revenue $13.3B; raises FY2024 guidance","bullets":["Revenues $13.3B, +2% YoY (+3% operational); non-COVID revenue grew 14% operationally.","Adjusted diluted EPS $0.60, vs $0.67 prior year; includes $1.3B one-time manufacturing optimization costs.","Raised FY2024 revenue guidance to $59.5-$62.5B (from $58.5-$61.5B) and adjusted EPS to $2.45-$2.65 (from $2.15-$2.35).","Launched Manufacturing Optimization Program targeting ~$1.5B cost savings by end of 2027; one-time costs ~$1.7B.","CSO Dr. Mikael Dolsten to depart; successor search underway."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-24-000155","json":"https://secwatch.observer/filing/0000078003-24-000155.json","markdown":"https://secwatch.observer/filing/0000078003-24-000155.md","text":"https://secwatch.observer/filing/0000078003-24-000155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000155/0000078003-24-000155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000155/pfe-20240730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:31:46.397729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}